Insider Buying: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Buys $5,760,544.86 in Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Bros. Advisors Lp Baker acquired 15,666 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Wednesday, November 4th. The shares were purchased at an average cost of $367.71 per share, for a total transaction of $5,760,544.86. Following the purchase, the director directly owned 1,964,542 shares in the company, valued at $722,381,738.82. The trade was a 0.80% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Bros. Advisors Lp Baker also recently made the following trade(s):

• On Friday, November 6th, Bros. Advisors Lp Baker acquired 76,140 shares of Madrigal Pharmaceuticals stock. The shares were purchased at an average price of $384.32 per share, with a total value of $29,262,124.80.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ:MDGL opened at $399.63 on Monday. Madrigal Pharmaceuticals, Inc. has a 52 week low of $353.54 and a 52 week high of $615.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.78 and a current ratio of 3.05. The company has a market capitalization of $9.28 billion, a PE ratio of -66.83 and a beta of -0.98. The company has a 50 day moving average price of $486.74 and a two-hundred day moving average price of $497.41.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, topping the consensus estimate of ($1.09) by $2.92. The company had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 10.89% and a negative return on equity of 27.08%. During the same period last year, the business posted ($5.08) earnings per share. Analysts forecast that Madrigal Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Institutional Trading of Madrigal Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Concurrent Investment Advisors LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 2.0% in the second quarter. Concurrent Investment Advisors LLC now owns 1,034 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 20 shares during the period. Fifth Third Bancorp increased its position in shares of Madrigal Pharmaceuticals by 3.5% during the third quarter. Fifth Third Bancorp now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 28 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Madrigal Pharmaceuticals by 2.7% during the third quarter. Commonwealth Equity Services LLC now owns 1,664 shares of the biopharmaceutical company’s stock worth $839,000 after acquiring an additional 43 shares in the last quarter. ProShare Advisors LLC raised its holdings in shares of Madrigal Pharmaceuticals by 5.5% during the third quarter. ProShare Advisors LLC now owns 838 shares of the biopharmaceutical company’s stock worth $422,000 after acquiring an additional 44 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Madrigal Pharmaceuticals by 35.4% during the second quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 45 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
• Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
• Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
• Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement

Analyst Ratings Changes

Several analysts recently commented on MDGL shares. Truist Financial reaffirmed a “buy” rating and set a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 4th. Canaccord Genuity Group lifted their target price on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Wells Fargo & Company assumed coverage on Madrigal Pharmaceuticals in a research note on Monday, July 27th. They issued an “overweight” rating and a $685.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, October 15th. Finally, Barclays lowered their price target on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania.

Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Madrigal’s work centers on advancing medicines for liver disease, with Rezdiffra serving as its first approved therapy.